However, programmed death ligand 1 (PD-L1) expression—the only biomarker approved for clinical practice—and other candidate predictive biomarkers such as tumor mutational burden (TMB), and HLA expression insufficiently discriminate tumor responders from non-responders [2,3,4,5,6]. The gene discussed is CD274; the disease is neoplasm.